Moderna announces on Monday that it has submitted authorization requests for its vaccine against Covid-19 in adolescents aged 12 to 17 in the European Union.
He also made the same request in Canada.
The applications have been filed with the European Medicines Agency (EMA) and Health Canada.
Moderna's vaccine is currently only authorized for people 18 years of age and over.
Read alsoCovid-19: the events of the day live
A first vaccine, that of the Pfizer / BioNTech alliance, was authorized at the end of May for adolescents from 12 years old in the 27 countries of the European Union.
The latter is also already authorized for this age group in Canada.
Side effects similar to those in adults
Moderna announced at the end of May the full results of clinical trials on more than 3,700 participants aged 12 to 17 in the United States.
"We are encouraged that Moderna's vaccine against Covid-19 has been shown to be highly effective in preventing Covid-19 in adolescents," Moderna boss Stéphane Bancel said on Monday.
The vaccine was "generally well tolerated," said the US biotechnology company, with side effects similar to those seen in adults.
The company "also plans to apply for emergency use authorization from the United States Medicines Agency (FDA) to extend the authorization to use its vaccine to adolescents" in the United States.
